YARDLEY, Pennsylvania, Sept. 10, 2014 /PRNewswire/ -- Since 1974 Mapi has lead Patient-Centred Research and pioneered industry wide innovations in Pharmaceutical Market Research, Cross-Cultural adaptation of Patient Reported Outcomes and Post-Approval pharmaceutical Research. Initiating global programs such as the ERIQA group; launch of the PRO Harmonization Group (which brings together the members of ERIQA, ISOQOL, ISPOR and the 'Health Outcomes Committee' of PhRMA, and the FDA) and development of industry best practices in Patient Registries.

Logo - http://photos.prnewswire.com/prnh/20140618/119365

In a recent global conference call to celebrate the company's 40^th anniversary, Bernard Jambon, Mapi's Founder and Chairman of the Board said, "For 40 years, healthcare researchers, Pharmaceutical, Biotechnology and Medical Device companies around the world have depended on Mapi innovations, expertise and insight to gather Real-World Evidence. Mapi remains the industry leader in enabling global PRO Data harmonization, Cross-Cultural adaptation of Clinical Outcome Assessments as well as managing post-approval safety and efficacy research."

Fundamental to Mapi Group's vision is keeping patients at the centre of healthcare research. Mapi Group provides insight for solutions to the challenges faced by Regulators, Health Technology Assessment (HTAs) organizations, Healthcare payers and Pharmaceutical companies by enabling an integrated patient-focused approach from clinical research through to post-approval and commercializing of healthcare products. Mapi delivers the expertise and services used to meet regulatory requirements, accelerate commercialization and enable Strategic Market Access of life saving treatments.

James Karis, Mapi Group Chief Executive Officer, added, "The next 40 years for Mapi will be as strong and innovative as the last. We continue to make strategic investments in our people and services. We are dedicated to leading the industry in Patient-Centred Research that will help Pharmaceutical; Biotechnology and Medical Device companies meet their regulatory requirements and enable clinicians to better care for their patients."

About Mapi:

Mapi is the global leader in Patient-Centred Research services including Real-World Evidence, Post-Approval, Registries, Linguistic Validation, Health Economics, Strategic Market Access and through the Mapi Research Trust; the largest library of Clinical Outcome Assessments.

With 40 years of experience in administering and developing insight from Real-World Evidence. Mapi supports Life-Science companies, Government Funded Health agencies, Health Technology Assessment (HTA) providers, Accountable Care Organizations (ACOs) and Regulatory bodies in gathering and evaluating data on Therapies, Pharmaceuticals, Biologicals, and Medical devices. Visit http://www.mapigroup.com for more information.

SOURCE Mapi